Peter Lynch fit · Growth at a reasonable price (GARP)
Is Esperion Therapeutics, Inc. (ESPR) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
0/100
FNot a fit
1/6 criteria passed
Peter Lynch's Criteria, Applied to ESPR
PEG ≤ 1.0
key—
EPS CAGR ≥ 15%
key-45.4%
Revenue CAGR ≥ 10%
-12.9%
Net margin > 0
-34.8%
How ESPR Scores on Other Strategies
Live Financial Snapshot
Market cap
$626.17M
P/E (TTM)
-
ROIC (TTM)
26.87%
Gross margin
53.54%
Frequently Asked Questions
What is ESPR's Peter Lynch fit score?
ESPR scores 0/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own ESPR?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ESPR.
How often is this score updated?
ESPR's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends ESPR.